Antony Riley Buys Shares of Forte Biosciences, Inc. $FBRX
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Antony Riley, CHIEF FINANCIAL OFFICER at Forte Biosciences, Inc. ($FBRX), bought 22,000 shares at an average price of $0. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Forte Biosciences, Inc. Stock Down 77.2%
Shares of Forte Biosciences, Inc. ($FBRX) traded around $17.59 on Thursday, down 77.2% for the day.
Forte Biosciences, Inc. Earnings
Analysts Set New Price Targets
About Forte Biosciences, Inc.
Forte Biosciences, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for autoimmune and autoimmune-related diseases. The company offers products, such as its lead product candidate FB102, a proprietary molecule with applications for celiac disease, vitiligo, and alopecia areata; and services, including the clinical development and management of its Phase 2 clinical trials. Forte Biosciences, Inc. was incorporated in 2007 and is based in Dallas, Texas. As of August 27, 2026, Forte Biosciences, Inc. operates as a subsidiary of argenx SE.
Get Forte Biosciences, Inc. alerts
New 13F filings, insider trades, and analyst moves on $FBRX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.